Alveolar echinococcosis: Evaluation of therapeutic strategies

Expert Opinion on Orphan Drugs

Volumn 2, Issue 1, 2014, Pages 67-86

  Vuitton, Dominique A ^a,b   Bresson Hadni, Solange ^a,b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Albendazole; Alveolar echinococcosis; Echinococcus multilocularis; Health professional networking; in vitro drug testing; Interventional endoscopy; Interventional radiology; Liver imaging; Liver surgery and transplantation; Mebendazole; Pharmacokinetics and clinical pharmacology; Telemedicine

Indexed keywords

2 METHOXYESTRADIOL; 4 [4 (4 FLUOROPHENYL) 2 (METHYLTHIO) 1H IMIDAZOL 5 YL] N (1 PHENYLETHYL) 2 PYRIDINAMINE; ALBENDAZOLE; AMPHOTERICIN B; ARTESUNATE; BENZIMIDAZOLE; BENZOIC ACID; CASPOFUNGIN; CLORSULON; COTRIMOXAZOLE; CYCLOSPORIN A; DIHYDROARTEMISININ; DOXORUBICIN; EFLORNITHINE; FLUBENDAZOLE; GENISTEIN; IMIDAZOLE DERIVATIVE; ISOFLAVONE DERIVATIVE; ITRACONAZOLE; IVERMECTIN; MEBENDAZOLE; MEFLOQUINE; METHISOPRINOL; NITAZOXANIDE; RIFAMPICIN; TRICLABENDAZOLE;

ADVERSE DRUG REACTION; BILIARY STENOSIS; CHEMOTHERAPY; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; ECHINOCOCCOSIS; ECHINOCOCCUS MULTILOCULARIS; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LIVER INJURY; LIVER TRANSPLANTATION; MEASUREMENT; PALLIATIVE THERAPY; PATIENT CARE; PERCUTANEOUS DRAINAGE; PERENDOSCOPIC INTERVENTION; PHARMACODYNAMICS; RADICAL RESECTION; REVIEW; STENOSIS; TREATMENT INDICATION;

EID: 84896704616     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.870033     Document Type: Review

References (110)

1. WHO-Informal Working Group on Echinococcosis. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull WHO 1996;74:231-42
2. Bresson-Hadni S, Vuitton DA, Bartholomot B, et al. A twenty-year history of alveolar echinococcosis in humans. Analysis of a series of 117 patients from eastern France. Eur J Gastroenterol Hepatol 2000;12:327-36
3. Kern P. Clinical features and treatment of alveolar echinococcosis. Curr Opin Infect Dis 2010;23:505-12
4. Kern P. Medical treatment of echinococcosis under the guidance of Good Clinical Practice (GCP/ICH). Parasitol Int 2006;55(Suppl):S273-82
5. Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010;114:1-16
6. Vuitton DA, Zhou H, Bresson-Hadni S, et al. Epidemiology of alveolar echinococcosis with particular reference to China and Europe. Parasitology 2003;127(Suppl):S87-107
7. Vuitton DA, Wang Q, Zhou HX, et al. A historical view of alveolar echinococcosis, 160 years after the discovery of the first case in humans: part 1. What have we learnt on the distribution of the disease and on its parasitic agent? Chin Med J (Engl) 2011;124:2943-53
8. Vuitton DA, Zhang SL, Yang Y, et al. Survival strategy of Echinococcus multilocularis in the human host. Parasitol Int 2006;55(Suppl):S51-5
9. Otero-Abad B, Torgerson PR. A systematic review of the epidemiology of echinococcosis in domestic and wild animals. PLoS Negl Trop Dis 2013;7(6):e2249
10. Bruzinskaite R, Marcinkute A, Strupas K, et al. Alveolar echinococcosis, Lithuania. Emerg Infect Dis 2007;13:1618-19
11. Knapp J, Staebler S, Bart JM, et al. Echinococcus multilocularis in Svalbard, Norway: microsatellite genotyping to investigate the origin of a highly focal contamination. Infect Genet Evol 2012;12:1270-4
12. Wahlstrom H, Lindberg A, Lindh J, et al. Investigations and actions taken during 2011 due to the first finding of Echinococcus multilocularis in Sweden. Euro Surveill 2012;17(28):20215 Available from: http://www. eurosurveillance. org/ViewArticle.aspx? ArticleId=20215 [Accessed 19 November 2013]
13. Deplazes P, Hegglin D, Gloor S, et al. Wilderness in the city: the urbanization of Echinococcus multilocularis. Trends Parasitol 2004;20:77-84
14. Schweiger A, Ammann RW, Candinas D, et al. Human alveolar echinococcosis after fox population increase, Switzerland. Emerg Infect Dis 2007;13:878-82
15. Romig T. Echinococcus multilocularis in Europe-state of the art. Vet Res Commun 2009;33(Suppl 1):31-4
16. Gesy K, Hill JE, Schwantje H, et al. Establishment of a European-type strain of Echinococcus multilocularis in Canadian wildlife. Parasitology 2013;140:1133-7
17. Torgerson PR, Keller K, Magnotta M, et al. The global burden of alveolar echinococcosis. PLoS Negl Trop Dis 2010;4:e722
18. Bresson-Hadni S, Laplante JJ, Lenys D, et al. Seroepidemiologic screening of Echinococcus multilocularis infection in a European area endemic for alveolar echinococcosis. Am J Trop Med Hyg 1994;51:837-46
19. Torgerson PR, Schweiger A, Deplazes P, et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol 2008;49:72-7
20. Bresson-Hadni S, Miguet JP, Mantion GA, Vuitton DA. Echinococcosis of the liver. In: Rodes J, Benhamou JP, Blei AT, editors. Textbook of hepatology: from basic science to clinical practice. 3rd edition. Blackwell Publishing; Oxford: 2007. p. 1047-57
21. Lacey E. The role of cytosqueletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 1968;18:885-6
22. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 1997;64:79-93
23. Taylor DH, Morris DL. In vitro culture of Echinococcus multilocularis: protoscolicidal action of praziquantel and albendazole sulphoxide. Trans R Soc Trop Med Hyg 1988;82:265-7
24. Eckert J, Burkhardt B. Chemotherapy of experimental echinococcosis. Acta Trop 1980;37:297-300
25. Taylor DH, Morris DL, Richards KS, et al. Echinococcus multilocularis: in vivo results of therapy with albendazole and praziquantel. Trans R Soc Trop Med Hyg 1988;82:611-15
26. Taylor DH, Morris DL, Reffin D, et al. Comparison of albendazole, mebendazole and praziquantel chemotherapy of Echinococcus multilocularis in a gerbil model. Gut 1989;30:1401-5
27. Davis A, Pawlowski ZS, Dixon H. Multicentre clinical trials of benzimidazole carbamates in human echinococcosis. Bull WHO 1986;64:383-8
28. Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of benzimidazole carbamates in human cystic echinococcosis (phase 2). Bull WHO 1989;67:503-8
29. Shuhua X, Jiqing Y, Mingjie W, et al. Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcus granulosus or Echinococcus multilocularis. Acta Trop 2002;82:77-84
30. Wen H, New RR, Muhmut M, et al. Pharmacology and efficacy of liposomeentrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology 1996;113:111-21
31. Ahmadnia S, Moazeni M, Mohammadi-Samani S, et al. In vivo evaluation of the efficacy of albendazole sulfoxide and albendazole sulfoxide loaded solid lipid nanoparticles against hydatid cyst. Exp Parasitol 2013;135:314-19
32. Liu Y, Wang XQ, Ren WX, et al. Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats. J Biomed Mater Res B Appl Biomater 2013;101:998-1005
33. Mukherjee T, Plakogiannis FM. Development and oral bioavailability assessment of a supersaturated selfmicroemulsifying drug delivery system (SMEDDS) of albendazole. J Pharm Pharmacol 2010;62:1112-20
34. Steiger U, Cotting J, Reichen J. Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Clin Pharmacol Ther 1990;47:347-53
35. Ingold K, Bigler P, Thormann W, et al. Efficacies of albendazole sulfoxide and albendazole sulfone against In vitrocultivated Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 1999;43:1052-61
36. Cotting J, Zeugin T, Steiger U, et al. Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol 1990;38:605-8
37. Nagy J, Schipper HG, Koopmans RP, et al. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg 2002;66:260-3
38. Dawson M, Braithwaite PA, Roberts MS, Watson TR. The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. Br J Clin Pharmacol 1985;19:79-86
39. Braithwaite PA, Roberts MS, Allan RJ, Watson TR. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol 1982;22:161-9
40. Witassek F, Bircher J. Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol 1983;25:85-90
41. Grenouillet F, Brientini MP, Richou C, et al. Evidence of intralesional diffusion of albendazole sulphoxide in patients with liver alveolar echinococcosis [abstract]. J Hepatol 2013;58(Suppl 1):S381
42. Zeugin T, Zysset T, Cotting J. Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its active metabolite albendazole sulfoxide. Ther Drug Monit 1990;12:187-90
43. Wojnicz A, Cabaleiro-Ocampo T, Román-Mart?́nez M, et al. A simple assay for the simultaneous determination of human plasma albendazole and albendazole sulfoxide levels by high performance liquid chromatography in tandem mass spectrometry with solidphase extraction. Clin Chim Acta 2013;426, C:58-63
44. Edwards G, Breckenridge AM. Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet 1988;15:67-93
45. Liu YH, Wang XG, Chen YT. Preliminary observation of continuous albendazole therapy in alveolar echinococcosis. Chin Med J 1991;104:930-3
46. Horton RJ. Chemotherapy of Echinococcus infection in man with albendazole. Trans R Soc Trop Med Hyg 1989;83:97-102
47. Wilson JF, Rausch RL, McMahon BJ, et al. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992;15:234-49
48. Ammann RW. Improvement of liver resectional therapy by adjuvant chemotherapy in alveolar hydatid disease. Swiss Echinococcosis Study Group (SESG). Parasitol Res 1991;77:290-3
49. Ammann RW, Ilitsch N, Marincek B, et al. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology 1994;19:735-42
50. Ishizu H, Uchino J, Sato N, et al. Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Hepatology 1997;25:528-31
51. Ricard-Blum S, Bresson-Hadni S, Grenard P, et al. The level of the collagen cross-link pyridinoline reflects the improvement of cutaneous lesions in one case of skin alveolar echinococcosis. Parasitol Res 1998;84:715-19
52. Lidove O, Chauveheid MP, Papo T, et al. Echinococcus multilocularis massive pericardial infection: late and dramatic improvement under albendazole therapy. Am J Med 2005;118:195-7
53. Bresson-Hadni S, Miguet JP, Lenys D, et al. Recurrence of alveolar echinococcosis in the liver graft after liver transplantation. Hepatology 1992;16:279-80
54. Koch S, Bresson-Hadni S, Miguet JP, et al. Experience of liver transplantation for incurable alveolar echinococcosis: a 45-case European collaborative report. Transplantation 2003;75:856-63
55. Kadry Z, Renner EC, Bachmann LM, et al. Evaluation of treatment and longterm follow-up in patients with hepatic alveolar echinococcosis. Br J Surg 2005;92:1110-16
56. Piarroux M, Piarroux R, Giorgi R, et al. Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients. J Hepatol 2011;55:1025-33
57. Bresson-Hadni S, Blagosklonov O, Knapp J, et al. Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year followup study. Liver Transpl 2011;17:855-65
58. Bardonnet K, Vuitton DA, Grenouillet F, et al. 30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient. Ann Clin Microbiol Antimicrob 2013;12:1
59. Vanparijs O. Chemotherapy of experimental Echinococcus multilocularis in jirds. Parasitol Res 1990;76:238-40
60. Lassègue A, Estavoyer JM, Minazzi H, et al. Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study. Gastroenterol Clin Biol 1984;8(4):314-20; in French
61. Richter D, Richter J, Grüner B, et al. In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis. Parasitol Res 2013;112:1655-60
62. Miyaji S, Katakura K, Matsufuji S, et al. Failure of treatment with alphadifluoromethylornithine against secondary multilocular echinococcosis in mice. Parasitol Res 1993;79:75-6
63. Sarciron ME, Walbaum S, Petavy AF. Effects of Isoprinosine on Echinococcus multilocularis and E. granulosus metacestodes. Parasitol Res 1995;81:329-33
64. Liance M, Bresson-Hadni S, Vuitton DA, et al. Effects of cyclosporin A on the course of murine alveolar echinococcosis and on specific cellular and humoral immune responses against Echinococcus multilocularis. Int J Parasitol 1992;22:23-8
65. Liance M, Nemati F, Bories C, et al. Experience with doxorubicin-bound polyisohexylcyanoacrylate nanoparticles on murine alveolar echinococcosis of the liver. Int J Parasitol 1993;23:427-9
66. Reuter S, Merkle M, Brehm K, et al. Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrob Agents Chemother 2003;47:620-5
67. Reuter S, Buck A, Grebe O, et al. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrob Agents Chemother 2003;47:3586-91
68. Reuter S, Beisler T, Kern P. Combined albendazole and amphotericin B against Echinococcus multilocularis in vitro. Acta Trop 2010;115:270-4
69. Reuter S, Manfras B, Merkle M, et al. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrob Agents Chemother 2006;50:2966-70
70. Stettler M, Fink R, Walker M, et al. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003;47:467-74
71. Kern P, Abboud P, Kern W, et al. Critical appraisal of nitazoxanide for the treatment of alveolar echinococcosis [abstract]. Am J Trop Med Hyg 2008;79:119
72. Stettler M, Rossignol JF, Fink R, et al. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 2004;34:615-24
73. Stadelmann B, Scholl S, Müller J, et al. Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. J Antimicrob Chemother 2010;65:512-19
74. Naguleswaran A, Spicher M, Vonlaufen N, et al. In vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multilocularis and Echinococcus granulosus. Antimicrob Agents Chemother 2006;50:3770-8
75. Spicher M, Naguleswaran A, Ortega-Mora LM, et al. In vitro and in vivo effects of 2-methoxyestradiol, either alone or combined with albendazole, against Echinococcus metacestodes. Exp Parasitol 2008;119:475-82
76. Spicher M, Roethlisberger C, Lany C, et al. In vitro and in vivo treatments of Echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives. Antimicrob Agents Chemother 2008;52:3447-50
77. Küster T, Stadelmann B, Hermann C, et al. In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis. Antimicrob Agents Chemother 2011;5:713-21
78. Stadelmann B, Küster T, Scholl S, et al. In vitro efficacy of dicationic compounds and mefloquine enantiomers against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2011;55:4866-72
79. Küster T, Kriegel N, Boykin DW, et al. In vitro and in vivo activities of dicationic diguanidino compounds against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2013;57:3829-35
80. Küster T, Lense N, Barna F, et al. A new promising application for highly cytotoxic metal compounds: h6-areneruthenium (II) phosphite complexes for the treatment of alveolar echinococcosis. J Med Chem 2012;55:4178-88
81. Gelmedin V, Caballero-Gamiz R, Brehm K. Characterization and inhibition of a p38-like mitogenactivated protein kinase (MAPK) from Echinococcus multilocularis: antiparasitic activities of p38 MAPK inhibitors. Biochem Pharmacol 2008;76:1068-81
82. Müller J, Limban C, Stadelmann B, et al. Thioureides of 2-(phenoxymethyl) benzoic acid 4-R substituted: a novel class of anti-parasitic compounds. Parasitol Int 2009;58:128-35
83. Vuitton DA, Gottstein B. Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay. J Biomed Biotechnol 2010;2010:923193
84. Liance M, Ricard-Blum S, Emery I, et al. Echinococcus multilocularis infection in mice: in vivo treatment with a low dose of IFN-gamma decreases metacestode growth and liver fibrogenesis. Parasite 1998;5:231-7
85. Emery I, Leclerc C, Sengphommachanh K, et al. In vivo treatment with recombinant IL-12 protects C57BL/6J mice against secondary alveolar echinococcosis. Parasite Immunol 1998;20:81-91
86. Jenne L, Kilwinski J, Radloff P, et al. Clinical efficacy of and immunologic alterations caused by interferon gamma therapy for alveolar echinococcosis. Clin Infect Dis 1998;26:492-4
87. Harraga S, Godot V, Bresson-Hadni S, et al. Clinical efficacy of and switch from T helper 2 to T helper 1 cytokine profile after interferon alpha2a monotherapy for human echinococcosis. Clin Infect Dis 1999;29:205-6
88. Godot V, Harraga S, Podoprigora G, et al. In vivo treatment with IFNalpha-2a protects C57BL/6J mice against a helminth infection of the liver and modulates immune responses. Gastroenterology 2003;124:1441-50
89. Gruener B, Cretu CM, Brunetti E, et al. Accelerated larval growth of Echinococcus spp. in the immunodeficient host? [abstract]. Am J Trop Med Hyg 2008;6:118
90. Weiner SM, Krenn V, Koelbel C, et al. Echinococcus multilocularis infection and TNF inhibitor treatment in a patient with rheumatoid arthritis. Rheumatol Int 2011;31:1399-400
91. Kern P, Gruener B, Wahlers K. Diagnosis and course of echinococcocal diseases in the transplant setting. Transpl Infect Dis 2011;13:217-21
92. Chauchet A, Grenouillet F, Knapp J, et al. Emergence of a new opportunistic infection in Europe: hepatic alveolar echinococcosis. Fifty case-report [abstract]. J Hepatol 2013;58(Suppl 1):S381
93. Buttenschoen K, Carli-Buttenschoen D, Gruener B, et al. Long-term experience on surgical treatment of alveolar echinococcosis. Langenbecks Arch Surg 2009;394:689-98
94. Buttenschoen K, Gruener B, Carli-Buttenschoen D, et al. Palliative operation for the treatment of alveolar echinococcosis. Langenbecks Arch Surg 2009;394:199-204
95. Ayifuhan A, Tuerganaili A, Jun C, et al. Surgical treatment for hepatic alveolar echinococcosis: report of 50 cases. Hepatogastroenterology 2012;59:790-3
96. Wen H, Dong JH, Zhang JH, et al. Ex vivo liver resection followed by autotransplantation for end-stage hepatic alveolar echinococcosis. Chin Med J (Engl) 2011;124:2813-17
97. Bresson-Hadni S, Delabrousse E, Blagosklonov O, et al. Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. Parasitol Int 2006;55(Suppl):S267-72
98. Grenouillet F, Frider B, Alvarez Rodriguez J, et al. Molecular diagnosis of polycystic echinococcosis due to Echinococcus vogeli in a Paraguayan immigrant in Argentina. J Clin Microbiol 2013;51:3151-3
99. Bartholomot B, Vuitton DA, Harraga S, et al. Combined ultrasound and serologic screening for hepatic alveolar echinococcosis in central China. Am J Trop Med Hyg 2002;66:23-9
100. Reuter S, Schirrmeister H, Kratzer W, et al. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis 1999;29:1157-63
101. Caoduro C, Porot C, Vuitton DA, et al. The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis. J Nucl Med 2013;54:358-63
102. Kern P, Wen H, Sato N, et al. WHO classification of alveolar echinococcosis: principles and application. Parasitol Int 2006;55(Suppl):S283-7
103. Reuter S, Nüssle K, Kolokythas O, et al. Alveolar liver echinococcosis: a comparative study of three imaging techniques. Infection 2001;29:119-25
104. Wang J, Xing Y, Ren B, et al. Alveolar echinococcosis: correlation of imaging type with PNM stage and diameter of lesions. Chin Med J (Engl) 2011;124:2824-8
105. Reuter S, Jensen B, Buttenschoen K, et al. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother 2000;46:451-6
106. Vogel J, Gorich J, Kramme E, et al. Alveolar echinococcosis of the liver: Percutaneous stent therapy in Budd-Chiari syndrome. Gut 1996;39:762-4
107. Reuter S, Buck A, Manfras B, et al. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 2004;39:509-17
108. Ammann RW, Renner EC, Gottstein B, et al. Immunosurveillance of alveolar echinococcosis by specific humoral and cellular immune tests: long-term analysis of the Swiss chemotherapy trial (1976-2001). J Hepatol 2004;41:551-9
109. Tappe D, Frosch M, Sako Y, et al. Close relationship between clinical regression and specific serology in the follow-up of patients with alveolar echinococcosis in different clinical stages. Am J Trop Med Hyg 2009;80:792-7
110. Crouzet J, Grenouillet F, Delabrousse E, et al. Personalized management of patients with inoperable alveolar echinococcosis undergoing treatment with albendazole: usefulness of positron-emission-tomography combined with serological and computed tomography follow-up. Clin Microbiol Infect 2010;16:788-91